Startups innovating for safe treatments for hemophilia, cholestasis and liver disease, full-stack mobile manipulation solutions, precision in dental implantology, and fully electric training and traveling airplane each receive CHF 10,000

22.03.2024

BLEEDnFIRE Therapeutics, CALDRE, DynaTech, IMPLANZ, and Milan Aircraft were selected at Venture Kick's first financial and entrepreneurial support stage. Their projects develop innovative and safe treatments for hemophilia and Von Willebrand disease.; injury prevention capabilities in pre-clinical models by leveraging liver-specific technology; full-stack robotic mobile manipulation solutions designed to alleviate industry limitations; pioneering technology that accurately predicts dental implant stability pre-surgery; outstanding flight performances with fully electric training and traveling airplanes.

314.jpg
225.jpg
BLEEDnFIRE Therapeutics, from right to left: CEO & cofounder: Dr. Raja Prince-Eladnani, Chair BoD & cofounder Prof. Anne Angelillo-Scherrer, Expert scientist Dr. Rim Diab
CALDRE_VK.jpg
CALDRE: From left to right, Dr. Felix Baier, Professor Deborah Stroka, Dr. Nicolas Melin
DynaTech_VK.jpg
DynaTech: from left to right, CEO Eris Dhionis Sako, CTO Johannes Pankert, CPO Kenneth Blomqvist
IMPLANZ_VK.jpg
IMPLANZ: bottom up, CEO Nicolas Gasser, CTO Patrik Wili
MilanAirplane_VK.jpg
Milan Aircraft Team
BLEEDnFIRE Therapeutics: Advanced Safe Therapy for Hemophilia & Von Willebrand Disease
BLEEDnFIRE Therapeutics is at the forefront of developing innovative and safe treatments for hemophilia and Von Willebrand disease. These inherited bleeding disorders are marked by frequent, spontaneous bleeding episodes. They impact a significant number of individuals worldwide, with prevalence rates ranging from 1 in 1000 to 1 in 60,000. The limitations of current treatment options underscore the urgent need for alternative therapies. With a present market valuation of USD 14 billion, projected to grow to USD 22 billion by 2030, the demand for more effective treatments is clear.
BLEEDnFIRE Therapeutics team developed SLN140, an advanced therapeutic option for hemophilia and Von Willebrand disease. SLN140 targets and diminishes the activity of protein S (PS), a blood coagulation factor that inhibits clotting. Reducing PS levels, SLN140 facilitates clotting and minimizes bleeding risks in affected individuals. SLN140 belongs to a new category of RNA therapeutics (ATMP), distinguished by their affordability, ease of production, and capability to safely address previously challenging pathways. BLEEDnFIRE Therapeutics patents for SLN140 is granted in the US, Korea, Japan, and Israel, with patent nationalization processes underway in additional countries.
BLEEDnFIRE Therapeutics team commitment to innovation and excellence is empowered by collaborations with the University of Bern and the Inselspital facilities, supporting the completion of IND-enabling studies and progress toward clinical trials.
The Venture Kick funds will contribute to establishing SLN140 regulatory and toxicology plan.

CALDRE: Cholestasis and liver disease resolved
CALDRE addresses an important public health issue related to the rising incidence of liver disease. The liver produces and secretes approximately 800 milliliters of bile each day. However, conditions such as autoimmune diseases, unhealthy lifestyles, and blockages can obstruct bile flow from the liver causing a disease called cholestasis. Cholestasis produces enormous stress on the liver and can lead to severe and potentially life-threatening tissue damage. It is the current indication responsible for 10% of all liver transplants.
CALDRE has discovered an innovative and untapped therapeutic target to help relieve the symptoms of liver cholestasis. By leveraging a liver-specific targeted therapy, cholestasis-induced liver damage can be prevented in pre-clinical models. This new treatment option holds promise for 370,000 patients suffering from primary biliary cholangitis and primary sclerosing cholangitis who are unresponsive to the current standard of care.
The team from the University of Bern and Inselspital, is currently developing a lead candidate, with a phase I clinical trial on the horizon. The Venture Kick Stage I funding provides the opportunity to engage expert advice on the pre-clinical strategy.

DynaTech: Unlocking robots' true potential
Many industries across the globe are struggling due to labor shortages. Recent breakthroughs in robotic technologies have enabled robots to help but due to a lack of manipulation skills, they are currently limited to tasks such as infrastructure inspection or patrolling.
DynaTech offers full-stack robotic mobile manipulation solutions designed to alleviate these limitations. Drawing on over 25 years of combined team experience at the forefront of ETH's robotics research, the co-founders Eris Dhionis Sako, Johannes Pankert, and Kenneth Blomqvist, and a team of robotic specialists, provide tight integration of a powerful internally developed robotic arm and machine learning technologies that empower robots to tackle tasks previously deemed impossible. The latest leaps in robotic automation are poised to disrupt the global physical labor market which accounts for 50% of global GDP.
The Venture Kick funds will be used to improve our marketing material and establish contact with new customers through fairs and exhibition visits.
 
IMPLANZ: Pioneering Precision in Dental Implantology
IMPLANZ is transforming the dental implant field with its pioneering technology that accurately predicts implant stability pre-surgery. Utilizing a blend of calibrated DVT images and computer simulations, IMPLANZ's solution offers dentists a revolutionary approach to treatment planning. The startup is enabling higher revenues for dentists while also enabling to treat more patients with a higher quality and patient satisfaction. 
Originating from the University of Bern, IMPLANZ's IMPLANZ CEO Nicolas Gasser and CTO Patrik Wili bring together a rich mix of expertise in computer science, biomedical engineering and business development, all dedicated to enhancing patient outcomes and streamlining dental procedures. With IMPLANZ, dentists are equipped with the data needed to ensure optimal implant placement, setting a new standard in patient care and treatment success.
The Venture Kick funds will be used for market exploration and validating product market fit. 
 
Milan Aircraft: Fully electric training and traveling airplane
Small aircraft aviation is facing increasing costs and pressure to reduce noise and CO2 emissions, but simply electrifying existing airframes results in non-satisfying flight performance due to heavy batteries. Endurance and range are far away from allowing full standard training.
The Milan concept, which is ‘electric by design’, addresses this problem and achieves outstanding flight performances. A usable endurance of ~ 2.5 hours fulfills more than 95% of all use-cases of flying school and clubs, at drastically reduced operational costs. The usable range of ~500km makes it also a true alternative for private owners.
The company is being founded by 11 experienced engineers, who specialize in fields like electric vehicles, power electronics, energy infrastructure, mechanics, software, aviation, or business advice. The revolution will not only relate to the propulsion system but also include a new way of industrial aircraft manufacturing. Furthermore, a brand-new European certification regulation, aiming to boost innovation, will be applied.
The Venture Kick funds will contribute to functional prototype building and to prepare for certification.

Additional Links